The antibody therapeutic failed to meet its primary endpoint in a Phase III study.
On August 14, 2017, Regeneron Pharmaceuticals announced plans to discontinue further clinical development of suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), because it did not meet its primary endpoint in a Phase III study of preventing medically-attended RSV infections in infants. Suptavumab did show signs of efficacy in a subgroup of patients. Adverse events were generally balanced between suptavumab and placebo. Data from the study will be presented at a future medical congress.
"We are disappointed in these results, as we had hoped suptavumab might offer a new option for the thousands of infants impacted by serious RSV infections every year," said George D. Yancopoulos, MD, PhD, president and chief scientific officer of Regeneron in a company press release. "Regeneron has a robust pipeline across many serious diseases, and we look forward to important data readouts from other programs in the coming weeks and months."
